Hepatic fat & fatty liver
One of 4 mechanistic pathways to 📉 Metabolic health & insulin sensitivity · 18 options
The liver is where insulin resistance usually starts. Fat accumulating in hepatocytes impairs insulin's ability to suppress glucose output, which raises circulating insulin, which drives more storage. Break that loop and the systemic picture follows.
An ALT above 30 with insulin resistance is fatty liver until proven otherwise, even inside the 'normal' range — the reference range was set on a population that largely had it. The ELF score estimates fibrosis without a biopsy.
Comprehensive Metabolic Panel (CMP)Enhanced Liver Fibrosis (ELF) TestFasting InsulinHbA1c (Hemoglobin A1c)Lipid Panel (Cholesterol, HDL, LDL, Triglycerides)FerritinUric Acid🫀 Fatty Liver & Liver Health covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
💉 Retatrutide
The glucagon component drives hepatic fat oxidation directly. Phase-2 liver-fat reductions were substantial and are among the most striking results in the field.
💉 Survodutide
GLP-1/glucagon with MASH as an explicit development target.
💉 Pemvidutide
A GLP-1/glucagon dual developed with hepatic fat and lean-mass preservation as the explicit design targets rather than as secondary endpoints.
💉 Semaglutide
Improves steatohepatitis resolution in randomized trials, largely via weight loss.
💉 Tesamorelin
Reduces visceral AND hepatic fat in trials, with the GH axis as the mechanism rather than appetite.
💉 Metformin
Reduces hepatic glucose output; the liver-fat effect is modest.
🧬 Berberine
Trials show reduced hepatic steatosis alongside its lipid and glucose effects.
🧬 TUDCA
Reduces endoplasmic reticulum stress in hepatocytes — a mechanism upstream of the fat accumulation itself.
🧬 Milk Thistle (Siliphos)
Silybin phytosome improves liver enzymes and, in some trials, steatosis. The phytosome form is what was studied.
🧬 Choline Bitartrate
Choline is required to package fat into VLDL for export. Deficiency causes fatty liver directly and reproducibly in humans — one of the cleanest nutrient-disease relationships known.
🧬 Phosphatidylcholine
The form choline is used in for lipoprotein assembly.
🧬 Betaine Anhydrous (TMG)
Methyl donor that supports phosphatidylcholine synthesis; trials show improved liver enzymes.
🧬 Omega-3 (Fish Oil)
Reduces hepatic triglyceride content in meta-analysis.
🧬 Vitamin E
The PIVENS trial showed histological improvement in non-diabetic NASH — one of few things with biopsy-proven benefit.
🧬 NAC
Glutathione restoration in a tissue with very high oxidative load.
💉 Lipo-C
Methionine, inositol and choline — the lipotropic combination aimed directly at hepatic fat export.
🧬 Artichoke Leaf Extract
Trials show reduced liver enzymes and improved steatosis on ultrasound.
💉 CMS-121
Inhibiting ACC1 or FASN is the textbook way to cut hepatic de novo lipogenesis, and in mice it read out that way — liver triglycerides and free fatty acids down, liver NF-kappaB, IL-18, caspase 3 and CRP down, and in normally aging mice hepatic caspase 1, caspase 3 and NOX4 down. The counterweight belongs in the same breath: when this enzyme step is blocked pharmacologically in humans, serum triglycerides have gone UP, not down. Anyone using it for a liver reason should be drawing a lipid panel, not assuming the mouse direction.
What actually decides this outcome, in order of size
One number decides this outcome and it is not on the list of seventeen: the percentage of body weight lost. Everything else on this page is either a way of achieving that percentage or a supporting act.
- Weight loss, on a dose-response curve steep enough to be a prescription. In 293 patients with biopsy-proven steatohepatitis followed for 52 weeks, 72 (25%) achieved resolution and 56 (19%) had regression of fibrosis. Among those losing at least 5% of body weight, 51 of 88 (58%) achieved resolution and 72 of 88 (82%) had a 2-point reduction in activity score (P<0.001) Vilar-Gomez 2015. The 7 to 10% band is where fibrosis starts to move, and no capsule on this page has a histologic endpoint at all.
- Fructose and alcohol specifically, not calories in general. Both bypass phosphofructokinase regulation and feed de novo lipogenesis directly, which is why two diets of equal energy produce different hepatic fat.
- Visceral rather than subcutaneous fat. Portal drainage means visceral adipose delivers free fatty acids straight to the hepatocyte, which is why Tesamorelin is on this page: it is a GHRH analog with a visceral-specific effect rather than a general weight agent.
- The incretin drugs, because they deliver the percentage. Subcutaneous semaglutide was tested against placebo in steatohepatitis with a histologic endpoint Newsome 2021, and the GLP-1-plus-glucagon agents on this page add a hepatic oxidation arm on top of the appetite one.
- The first drug approved for the disease itself. Resmetirom is a liver-directed thyroid hormone receptor-beta agonist tested in a phase 3 trial with paired biopsies Harrison 2024. It is the comparator every supplement on this page is now measured against.
- The hepatoprotective shelf, last. Real mechanisms, no histologic outcome data.
The order to run these in, and what has to be true first
Stage the liver, then move the percentage, then support. Buying the support first is the standard mistake and it is expensive in years.
- Stage the fibrosis before anything else. Comprehensive Metabolic Panel (CMP) gives ALT, AST and platelets, which is a FIB-4 score, and a sequential FIB-4 then Enhanced Liver Fibrosis (ELF) Test approach is the validated way to find advanced fibrosis without biopsying everybody Kang 2024. A normal ALT does not exclude it: advanced fibrosis and steatosis are found at meaningful rates in people whose aminotransferases sit inside the reference interval Makker 2021, and the reference interval itself was drawn from populations containing undiagnosed fatty liver, which is why the upper limit has been revised downward Choi 2024.
- Fix the input, and set the target as a percentage. 7 to 10% of body weight is the number with histologic evidence behind it Vilar-Gomez 2015. Alcohol to zero and fructose down, because both feed de novo lipogenesis independent of total energy.
- Then the agents that actually deliver the percentage. Semaglutide, Retatrutide, Survodutide and Pemvidutide act through appetite, with the glucagon arm adding hepatic fat oxidation; Tesamorelin targets visceral fat specifically; Metformin suppresses hepatic gluconeogenesis through AMPK and is a glycemic drug rather than a liver one.
- Then the mechanistically-argued support. Berberine as an AMPK activator, TUDCA as a bile acid reducing endoplasmic reticulum stress, Choline Bitartrate and Phosphatidylcholine because choline deficiency causes hepatic steatosis by starving VLDL export, Betaine Anhydrous (TMG) as a methyl donor for the same pathway, Omega-3 (Fish Oil) for triglyceride lowering, NAC as a glutathione precursor, and Vitamin E which has the strongest supplement evidence in non-diabetic steatohepatitis.
- Milk Thistle (Siliphos) and Artichoke Leaf Extract last. Silymarin has plausible antioxidant and antifibrotic mechanisms and no histologic outcome to point at.
What gets bought for this that cannot move it
No hepatoprotective supplement on this page has a paired-biopsy outcome. Weight loss does, with 58% resolution at a 5% threshold in 293 patients Vilar-Gomez 2015, and resmetirom does Harrison 2024. Milk thistle, choline and NAC are argued from mechanism, which this site is happy to do, but the mechanism is not the endpoint and on this disease the endpoint exists.
A normal ALT is the most reassuring wrong result in hepatology. Advanced fibrosis is found in people with aminotransferases inside the reference range Makker 2021, and the reference range was derived from cohorts that included undiagnosed fatty liver, which is why the upper limit has been revised downward Choi 2024. A reader who buys this pathway on the strength of a normal Comprehensive Metabolic Panel (CMP) has skipped the staging step, and fibrosis is the only feature here that predicts outcome.
Liver enzymes falling is not fibrosis improving. ALT can fall as steatohepatitis burns out into cirrhosis, so the direction of the number and the direction of the disease can be opposite. Only a fibrosis-specific measure such as Enhanced Liver Fibrosis (ELF) Test or a sequential FIB-4 approach separates them Kang 2024.
And if you drink, this is the wrong page. Alcohol-related and metabolic fatty liver look identical on ultrasound and on the Comprehensive Metabolic Panel (CMP), and only one of them is treated by anything listed above. A GGT (Gamma-Glutamyl Transferase) disproportionate to ALT is the cheapest hint.
How you would know it was working, on a real read-out and a real timescale
Hepatic fat responds faster than almost anything else in the body, which makes this one of the more rewarding goals to measure, provided you measure the right thing.
- Body weight as a percentage, weekly, with 7 to 10% as the target. This is the read-out with histologic evidence behind it Vilar-Gomez 2015, and it is free. Judge it at 24 weeks, not at 4, because the fibrosis effect appears at the top of the loss range.
- Comprehensive Metabolic Panel (CMP) at 12 weeks for ALT and AST. Hepatic fat falls before weight plateaus, and ALT typically moves within 8 to 12 weeks of a real dietary change. Read the fall as an input signal, not as fibrosis reversing.
- Enhanced Liver Fibrosis (ELF) Test at 12 months, not sooner. The enhanced liver fibrosis panel measures matrix turnover through hyaluronic acid, PIIINP and TIMP-1, and matrix remodels over months to years. Sequential FIB-4 then ELF is the validated order Kang 2024.
- Fasting Insulin at 12 weeks and HbA1c (Hemoglobin A1c) at 12 weeks. Insulin moves first because hepatic insulin sensitivity recovers within weeks of fat clearing; HbA1c cannot move faster than the 120-day red-cell lifespan allows.
- Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) with ApoB (Apolipoprotein B) and GGT (Gamma-Glutamyl Transferase) at 12 weeks. Hepatic VLDL export drives the triglyceride number, and GGT is the enzyme that separates an alcohol contribution from a metabolic one.
What will fool you. ALT falls with any weight loss including the first 2 kg, which is mostly glycogen and its bound water at about 3 g of water per gram of glycogen. It also falls in advancing cirrhosis. A statin started in the same window lowers ALT for reasons unrelated to fat, and a single bout of unaccustomed exercise raises AST from muscle for 3 to 5 days, which looks like a liver getting worse.
Sources read for these sections
- Vilar-Gomez E, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015;149(2):367-78 · PMID 25865049
- Newsome PN. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine 2021;384(12):1113-1124 · PMID 33185364
- Harrison SA. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. New England Journal of Medicine 2024 · PMID 38324483
- Makker J, et al. Prevalence of advanced liver fibrosis and steatosis in type-2 diabetics with normal transaminases: A prospective cohort study. World Journal of Gastroenterology 2021 · PMID 33642826
- Choi J, et al. Updated Reference Intervals for Alanine Aminotransferase in a Metabolically and Histologically Normal Population. Clinical Gastroenterology and Hepatology 2024 · PMID 38750867
- Kang YW, et al. Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Diagnostics 2024 · PMID 39594183
The other 3 routes to metabolic health & insulin sensitivity
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
You know the goal. Skool has the plan.
This pathway is one arm of The Metabolic health & insulin sensitivity Blueprint. The members' version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.
Open The Metabolic health & insulin sensitivity Blueprint in Skool →$10/mo, cancel anytime.
← Open this pathway in the interactive Vault
Frequently asked questions
The liver is where insulin resistance usually starts. Fat accumulating in hepatocytes impairs insulin's ability to suppress glucose output, which raises circulating insulin, which drives more storage. Break that loop and the systemic picture follows.
18 options are mapped to this pathway in the Vault, including Retatrutide, Survodutide, Pemvidutide, Semaglutide. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 16 carry clinical validation and 2 are mechanistic predictions.
An ALT above 30 with insulin resistance is fatty liver until proven otherwise, even inside the 'normal' range — the reference range was set on a population that largely had it. The ELF score estimates fibrosis without a biopsy. The markers worth checking are Comprehensive Metabolic Panel (CMP), Enhanced Liver Fibrosis (ELF) Test, Fasting Insulin, HbA1c (Hemoglobin A1c).
Unproven is not the same as ineffective. Of the 18 options on this pathway, 16 have clinical validation and 2 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.
Where this goes next
Everything above is the free case for Hepatic fat & fatty liver. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.